PDCD1 and neoplasm: ICB therapy aims to restore the antitumor immune response by blocking the interaction between immune checkpoint proteins, such as programmed cell death protein 1 (PD-1) and its ligand (PD-L1), thereby enhancing the activity of T cells against tumor cells.